Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (19576)	12/11/1998 11:42:00 AM
From: Mr.Manners	Read Replies (1) \| Respond to of 120523

Hi Jenna, thought this might be of interest, even if it is from Yahoo boards: ZILA News from Barrington, Pauli&Co and SUTRO I got these faxed to me by a friend who attended a special luncheon at the company yesterday. These reports should be on the wires soon. These reports were issued December 10, 1998: Here is a synopsis: 1) Barrington raises fiscal 1999 EPS estimate to $.15 and reiterates 1-BUY rating 2) Pauli & CO raises 12-18 mo target price to $14-$18 per share, or 30-33 times year 2000 earnings estimate of $.48 per share. "Due to strong 1st Q results and our increasing confidence in Zila's management and future, we are reiterating our BUY(1) rating on the stock." Also, they stated that it is highly likely that FDA approval will be received by early March, 1999. 3) Sutro&Co raises full-year estimate for this year by $.05 to $.15 per share. They expect FDA approval and launch by end of April, 1999. Expected short term impact is shares may strengthen. Sutro reiterates the purchase recommendation (strong Buy). Their 12 month target price is $15.